AI-Enabled POC Device Detects Cancers Without Biopsies
|
By LabMedica International staff writers Posted on 15 Sep 2022 |

Researchers have developed a unique type of nanoparticle called a “nanorattle” that greatly enhances light emitted from within its outer shell. Loaded with light scattering dyes called Raman reporters commonly used to detect biomarkers of disease in organic samples, the approach can amplify and detect signals from separate types of nanoprobes without needing an expensive machine or medical professional to read the results. In a small proof-of-concept study, the nanorattles accurately identified head and neck cancers through an AI-enabled point-of-care device that could revolutionize how these cancers and other diseases are detected in low-resource areas to improve global health.
To make nanorattles, researchers at Duke University (Durham, NC, USA) start with a solid gold sphere about 20 nanometers wide. After growing a layer of silver around the gold core to make a larger sphere (or cube), they use a corrosion process called galvanic replacement that hollows out the silver, creating a cage-like shell around the core. The structure is then soaked in a solution containing positively charged Raman reporters, which are drawn into the outer cage by the negatively charged gold core. The outer hulls are then covered by an extremely thin layer of gold to lock the Raman reporters inside. The result is a nanosphere (or nanocube) about 60 nanometers wide with an architecture that resembles a rattle - a gold core trapped within a larger outer silver-gold shell. The gap between the two is only about a few nanometers, which is just large enough to fit the Raman reporters. Those tight tolerances are essential to controlling the Raman signal enhancement the nanorattles produce.
When a laser shines on the nanorattles, it travels through the extremely thin outer shell and hits the Raman reporters within, causing them to emit light of their own. Because of how close the surfaces of the gold core and the outer gold/silver shell are together, the laser also excites groups of electrons on the metallic structures, called plasmons. These groups of electrons create an extremely powerful electromagnetic field due to the plasmons’ interaction of the metallic core-shell architecture, a process called plasmonic coupling, which amplifies the light emitted by the Raman reporters millions of times over. The researchers applied the nanorattle technology to a lab-on-a-stick device capable of detecting head and neck cancers, which appear anywhere between the shoulders and the brain, typically in the mouth, nose and throat. Survival rate for these cancers have hovered between 40 and 60% for decades. While those statistics have improved in recent years in the U.S., they have gotten worse in low-resource settings, where risk factors such as smoking, drinking and betel nut chewing are much more prevalent.
The prototype device uses specific genetic sequences that act like Velcro for the biomarkers the researchers are looking for - in this case, a specific mRNA that is overly abundant in people with head and neck cancers. When the mRNA in question is present, it acts like a tether that binds nanorattles to magnetic beads. These beads are then concentrated and held in place by another magnet while everything else gets rinsed away. Researchers can then use a simple, inexpensive handheld device to look for light emitted from the nanorattles to see if any biomarkers were caught. In the experiments, the test determined whether or not 20 samples came from patients that had head and neck cancer with 100% accuracy. The experiments also showed that the nanorattle platform is capable of handling multiple types of nanoprobes, thanks to a machine learning algorithm that can tease apart the separate signals, meaning they can target multiple biomarkers at once.
“In low-resource settings, these cancers often present in advanced stages and result in poor outcomes due in part to limited examination equipment, lack of trained healthcare workers and essentially non-existent screening programs,” said Walter Lee, professor of head and neck surgery & communication sciences and radiation oncology at Duke, and a collaborator on the research. “Having the ability to detect these cancers early should lead to earlier treatment and improvement in outcomes, both in survival and quality of life,” Lee said. “This approach is exciting since it does not depend on a pathologist review and potentially could be used at the point of care.”
“Many mRNA biomarkers are overly abundant in multiple types of cancers, while other biomarkers can be used to evaluate patient risk and future treatment outcome,” said Tuan Vo-Dinh, the R. Eugene and Susie E. Goodson Distinguished Professor of Biomedical Engineering and professor of chemistry at Duke. “Detecting multiple biomarkers at once would help us differentiate between cancers, and also look for other prognostic markers such as Human Papillomavirus (HPV), and both positive and negative controls. Combining mRNA detection with novel nanorattle biosensing will result in a paradigm shift in achieving a diagnostic tool that could revolutionize how these cancers and other diseases are detected in low-resource areas”.
Related Links:
Duke University
Latest Molecular Diagnostics News
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
- Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








